Targeting VPS34 in autophagy: An update on pharmacological small-molecule compounds

Eur J Med Chem. 2023 Aug 5:256:115467. doi: 10.1016/j.ejmech.2023.115467. Epub 2023 May 6.

Abstract

VPS34 is well-known to be the unique member of the class III phosphoinositide 3-kinase (PI3K) family, forming VPS34 complex 1 and complex 2, which are involved in several key physiological processes. Of note, VPS34 complex 1 is an important node of autophagosome generation, which controls T cell metabolism and maintains cellular homeostasis through the autophagic pathway. And, VPS34 complex 2 is involved in endocytosis as well as vesicular transport, and is closely related to neurotransmission, antigen presentation and brain development. Due to the two important biological functions of VPS34, its dysregulation can lead to the development of cardiovascular disease, cancer, neurological disorders, and many types of human diseases by altering normal human physiology. Thus, in this review, we not only summarize the molecular structure and function of VPS34, but demonstrate the relationships between VPS34 and human diseases. Moreover, we further discuss the current small molecule inhibitors targeting VPS34 based upon the structure and function of VPS34, which may provide an insight into the future targeted drug development.

Keywords: Autophagy; Drug development; Human disease; Small-molecule compound; VPS34.

Publication types

  • Review

MeSH terms

  • Autophagosomes / metabolism
  • Autophagy*
  • Class III Phosphatidylinositol 3-Kinases* / metabolism
  • Humans
  • T-Lymphocytes

Substances

  • Class III Phosphatidylinositol 3-Kinases